Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc. MRNA, -0.53% said it and GAVI, the Vaccine Alliance supplying vaccines to low- and middle-income countries, have agreed to cancel remaining orders under their 2022 COVID-19 vaccine agreement given "sufficient supply." The biotechnology company has supplied Gavi with nearly 70 million doses of COVID-19 vaccines, in addition to facilitating the donation of more than 100 million doses.

Moderna, Gavi cancel COVID-19 vaccine orders for rest of 2022 due to 'sufficient supply'

Given the sufficient supply of COVID-19 vaccines globally, Moderna & Gavi have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022 Gavi and Moderna have agreed to create a new framework that would enable Gavi to purchase up to 100 million doses of updated variant-specific COVID-19 vaccines in 2023, with all doses offered at Moderna's lowest-tiered price CAMBRIDGE, MA / ACCESSWIRE / October 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Gavi, the Vaccine Alliance, have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022. Moderna's agreement with Gavi has led to the supply of nearly 70 million doses of COVID-19 vaccines to the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries, in addition to the Company facilitating the donation of more than 100 million doses to these countries.

Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries

Abbott Labs

Pfizer

These stocks could be ready for big bounces.

3 Beaten-Down Stocks to Buy and Hold

COVID-19 vaccine Comirnaty and Paxlovid pill should contribute circa 55% to Pfizer's 2022 revenues. Pfizer's revenues from the U.S. government represented 26% of total revenues for Q2 2022, up from 13% reported in 2021.

The Importance Of Government Contracting For Pfizer And Moderna

1 Critical Thing About Moderna That the Market Is Ignoring

BioNTech SE

Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years.

FDA Allows Emergency Use of Omicron-Based COVID Jabs in Kids

Merck

Back in September 2021,Moderna's and Merck's market cap valuation were only a few billions apart at ~$175bn and ~$182bn, respectively. As the more diversified, future-proofed pharma, it makes sense that Merck's valuation has increased while Moderna's has tanked.

Merck And Moderna Move Forward With Melanoma Vaccine - There's A Case For Backing Both

Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.

Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab

CAMBRIDGE, MA / ACCESSWIRE / October 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 3, 2022 to report its third quarter 2022 financial results, and provide a corporate update.

Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Moderna (MRNA) Soars 8.3%: Is Further Upside Left in the Stock?

Moderna's revenue is declining as public resists boosting. The FDA approved the new booster for children aged 6 and up.

Moderna Now Priced Attractively For Long-Term Investors

The group that developed a Covid jab using messenger RNA (mRNA) technology has inked a US$250mln deal with to create a cancer vaccine with one of the world's largest pharma companies. Moderna Theraputics Inc is teaming up with Merck to develop and commercialise the personalised cancer drug mRNA-4157/V940, which is currently in phase II trials.

Moderna and Merck ink US$250mln deal to develop world's first cancer vaccine

Alcoa

Markets moved slightly lower in advance of the latest data on inflation.

These 2 Stocks Gave Investors a Nice Surprise Wednesday

Beyond Meat

Coinbase

Etsy

Peloton

Shopify

Block

This market downturn has not hit all stocks equally. While the major indices are down between 20% and 35% on the year, many stocks are down 70% or more in 2022.

7 Stocks That Could Sink Your Portfolio if You Don't Sell Now

The move is welcomed by investors because if successful, it would help Moderna diversify its revenue and profits away from COVID-19 vaccines.

Moderna pops 17% after Merck exercises option to jointly develop a personalized cancer vaccine

Shares of Moderna Inc (NASDAQ: MRNA) jumped as much as 15% this morning after the biotechnology company built on an agreement it signed with Merck & Co Inc (NYSE: MRK) in 2016.

Moderna shares jumped 15% on Wednesday: this is why

The Centers for Disease Control and Prevention officially signed off on allowing children as young as 5 years old to get an updated COVID-19 booster shot. CDC Director Rochelle Walensky signed the decision memo on Wednesday afternoon, the same day that the Food and Drug Administration expanded the authorizations for Moderna Inc. MRNA, +7.75% and BioNTech SE BNTX, +4.97% /Pfizer Inc.'s PFE, +0.66% updated COVID-19 boosters.

CDC officially recommends new boosters for young children

Like Moderna's and Pfizer's updated vaccines for adults, the child doses target newer strains of COVID-19.

FDA Authorizes New COVID Boosters for Kids

A cancer vaccine deal with pharma heavyweight Merck is lighting a fire underneath the biotech's shares today.

Why Moderna Stock Is Bolting Higher Today

Could this be a collaboration that saves lives? That's the billion-dollar question today as Moderna (NASDAQ: MRNA ) is reportedly working with Merck (NYSE: MRK ) to develop an mRNA-based cancer vaccine.

Why Is Moderna (MRNA) Stock Up 10% Today?

Shares of Moderna Inc. MRNA, +8.93% soared 9.4% in trading on Wednesday after the Food and Drug Administration said children between the ages of 6 and 17 years old can now get the bivalent COVID-19 booster developed by the company. The regulator also said that children between the ages of 5 and 11 years old can get the updated BioNTech SE BNTX, +5.71% /Pfizer Inc. PFE, +1.77% shot.

FDA said children between 6 and 17 can get Moderna's new COVID-19 booster

mRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron Variant Authorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent Vaccine Candidates CAMBRIDGE, MA / ACCESSWIRE / October 12, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children and adolescents 6 to 17 years of age. The authorizations are based on a 25 μg booster dose for children ages 6 to 11 years old and a 50 μg booster dose for adolescents 12 to 17 years old, each following a completed primary series of any of the authorized COVID-19 vaccines or a previous booster.

Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

Uptake of the retooled coronavirus vaccine among Americans 12 years and older has lagged.

FDA Authorizes Omicron-Specific Covid Boosters For Kids 5 And Up

Moderna's vaccine is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest form skin cancer.

Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients

U.S. health regulators authorized the use of Omicron-tailored COVID-19 booster shots from Moderna Inc and Pfizer Inc in children as young as 5, a move that will expand the government's fall vaccination campaign.

News for Moderna Stock (MRNA)